AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23820362 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat Trial for 'At Risk' group
Number of subjects: 56
Study 23820362 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mile run time for 'Not at Risk' group
Number of subjects: 56
Study 23820362 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight comparison
Number of subjects: 56
Study 21525251 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 2296
Study 19624856 — intervention group
Group type: EXPERIMENTAL
Intervention: NOP‐47 (5 g/day for 2 weeks)
Number of subjects: 20
Study 19624856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17163252 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 microg/kg
Number of subjects: 100
Study 17163252 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 microg/kg
Number of subjects: 100
Study 17163252 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 100
Study 17163252 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 80 microg/kg
Number of subjects: 100
Study 17163252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12659472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual grip selection task with wooden dowels
Number of subjects: 26
Study 10887385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 55
Study 10887385 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 150 mg/day
Number of subjects: 55
Study 8620265 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (physicians given socioeconomic status or profession)
Number of subjects: 336
Study 8620265 — intervention group
Group type: COMPARATOR
Intervention: Group B (physicians given scenarios without socioeconomic status or profession)
Number of subjects: 336
Study 1380588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine (20 mg b.i.d.) and doxazosin (2 mg o.d.)
Number of subjects: 0
Study 1380588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and doxazosin
Number of subjects: 0
Study 1380588 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 0
Study 1380588 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 3904643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administered intravenously at 10 ng/kg/min for 72 hours
Number of subjects: 55
Study 3904643 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously for 72 hours
Number of subjects: 55
Study 3904643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 55
Study 3904643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30949987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg twice a day)
Number of subjects: 91
Study 30949987 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 91
Study 29528914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell culture-derived subunit trivalent inactivated influenza vaccine (NBP607)
Number of subjects: 374
Study 29528914 — intervention group
Group type: COMPARATOR
Intervention: Egg-based control vaccine
Number of subjects: 374
Study 27893095 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Reading Independence (FRI) Index
Number of subjects: 100
Study 25831600 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Pro Health (CPH) - 700 ppm CPC
Number of subjects: 0
Study 25831600 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Puerto Rico (CT450) - 450 ppm CPC
Number of subjects: 0
Study 25831600 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total US (CT750) - 750 ppm CPC
Number of subjects: 0
Study 25831600 — intervention group
Group type: EXPERIMENTAL
Intervention: Scope Mouthwash (SCP) - 450 ppm CPC
Number of subjects: 0
Study 25831600 — intervention group
Group type: COMPARATOR
Intervention: Water control (CTR)
Number of subjects: 0
Study 22259810 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoelastic archwires (HANT)
Number of subjects: 30
Study 22259810 — intervention group
Group type: COMPARATOR
Intervention: Superelastic archwires (SE)
Number of subjects: 30
Study 20926040 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional phototherapy (Group I)
Number of subjects: 60
Study 20926040 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy (Group II)
Number of subjects: 60
Study 18070803 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal lactate steady state (MLSS) exercise on a cycle ergometer until exhaustion
Number of subjects: 11
Study 18070803 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal lactate steady state (MLSS) exercise
Number of subjects: 11
Study 16019236 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 30 days
Number of subjects: 21
Study 16019236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11920396 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 1.0 mg/kg + MTX
Number of subjects: 419
Study 11920396 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 2.0 mg/kg + MTX
Number of subjects: 419
Study 11920396 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 419
Study 11920396 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (0.04, 0.1, 0.4 mg/kg) + MTX
Number of subjects: 419
Study 11920396 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra + MTX
Number of subjects: 419
Study 10796060 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a dry powder inhaler (DPI) at 22 degrees C
Number of subjects: 14
Study 10796060 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a dry powder inhaler (DPI) at -10 degrees C
Number of subjects: 14
Study 10796060 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at 22 degrees C
Number of subjects: 14
Study 10796060 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at -10 degrees C
Number of subjects: 14
Study 10796060 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at -10 degrees C after 2000 microg
Number of subjects: 14
Study 8697553 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (2.5‐50 micrograms.kg‐1)
Number of subjects: 41
Study 8697553 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (dose-dependent)
Number of subjects: 41
Study 8697553 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1.2 mg)
Number of subjects: 41
Study 8697553 — intervention group
Group type: COMPARATOR
Intervention: Control group (ASA 1 or 2 patients with normally innervated hearts)
Number of subjects: 41
Study 1624649 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated pancreatic enzymes given before meals
Number of subjects: 8
Study 1624649 — intervention group
Group type: COMPARATOR
Intervention: Enteric coated pancreatic enzymes given during meals
Number of subjects: 8
Study 6734078 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sulphated bile acids
Number of subjects: 0
Study 6734078 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary bilirubin
Number of subjects: 0
Study 6734078 — intervention group
Group type: EXPERIMENTAL
Intervention: [3H]chenodeoxycholate-3-sulphate
Number of subjects: 0
Study 6734078 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C]glycocholate
Number of subjects: 0
Study 6734078 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive sulphated bile acids
Number of subjects: 0
Study 6734078 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary excretion of radioactive labelled sulphated bile acids
Number of subjects: 0
Study 31298357 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral hygiene session
Number of subjects: 10
Study 31298357 — intervention group
Group type: COMPARATOR
Intervention: GCF samples from not pregnant fertile women (control group)
Number of subjects: 10
Study 29496516 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA+estrogen/progestin therapy
Number of subjects: 70
Study 29496516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25872641 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-customised nutrition education programme (8 weekly sessions of 2-2.5 hours)
Number of subjects: 82
Study 25872641 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-customised nutrition education programme
Number of subjects: 82
Study 25872641 — intervention group
Group type: COMPARATOR
Intervention: Education materials only (control group)
Number of subjects: 82
Study 24615171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin HCl fixed-dose combination (FDC) capsules (0.5 mg/0.2 mg)
Number of subjects: 153
Study 24615171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin HCl FDC containing 15% by weight enteric-coated tamsulosin pellets
Number of subjects: 153
Study 24615171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin HCl FDC containing 15% by weight enteric-coated tamsulosin pellets combined with uncoated tamsulosin pellets (coated:uncoated = 10:90)
Number of subjects: 153
Study 24615171 — intervention group
Group type: COMPARATOR
Intervention: Commercial Avodart™ (dutasteride 0.5 mg) and Harnal-D™ Tablets (tamsulosin 0.2 mg)
Number of subjects: 153
Study 24615171 — intervention group
Group type: COMPARATOR
Intervention: Commercial Harnal™ Capsules (tamsulosin 0.2 mg)
Number of subjects: 153
Study 22366046 — intervention group
Group type: EXPERIMENTAL
Intervention: External cooling to achieve normothermia (36.5‐37°C) for 48 hours
Number of subjects: 200
Study 22366046 — intervention group
Group type: COMPARATOR
Intervention: No external cooling
Number of subjects: 200
Study 20718773 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0·02, 0·04, 0·08 and 0·16 mg protein/kg)
Number of subjects: 40
Study 20718773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17504357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate (7 mg for three consecutive nights)
Number of subjects: 57
Study 17504357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 15258718 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER fixed low dose (75 mg/day)
Number of subjects: 386
Study 15258718 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER flexible higher dose (150-225 mg/day)
Number of subjects: 386
Study 15258718 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER (at any dose)
Number of subjects: 386
Study 15258718 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 386
Study 10910491 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg meperidine
Number of subjects: 34
Study 10910491 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg meperidine
Number of subjects: 34
Study 10910491 — intervention group
Group type: COMPARATOR
Intervention: bupivicaine‐fentanyl
Number of subjects: 34
Study 9261669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pyridoxine and magnesium (HDPM) at an average dose of 638.9 mg of pyridoxine and 216.3 mg of magnesium oxide
Number of subjects: 12
Study 9261669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8275623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine salicylate
Number of subjects: 13
Study 8275623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3325468 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta‐containing cream
Number of subjects: 15
Study 3325468 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream base
Number of subjects: 15
Study 2810009 — intervention group
Group type: EXPERIMENTAL
Intervention: TC film (tetracycline immobilized on a collagen film)
Number of subjects: 5
Study 2810009 — intervention group
Group type: COMPARATOR
Intervention: Placebo film (tetracycline non-immobilized)
Number of subjects: 5
Study 31641071 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 40
Study 31641071 — intervention group
Group type: COMPARATOR
Intervention: NIV‐PSV
Number of subjects: 40
Study 31029880 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized normative feedback (PNF)
Number of subjects: 4460
Study 31029880 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized normative feedback (PNF) for motivated students (score ≥3)
Number of subjects: 4460
Study 31029880 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized normative feedback (PNF) for low-motivated students
Number of subjects: 4460
Study 31029880 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4460
Study 29121291 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pectoral nerve block2 (mPEC2)
Number of subjects: 62
Study 29121291 — intervention group
Group type: COMPARATOR
Intervention: Pectoral nerve block1 (PEC1)
Number of subjects: 62
Study 25468685 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal ankle joint cooling (crushed ice)
Number of subjects: 30
Study 25468685 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (candy corn)
Number of subjects: 30
Study 23172934 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide sustained release 1.5 mg ± perindopril 2 to 4 mg
Number of subjects: 284
Study 23172934 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 284
Study 22071710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1812
Study 22071710 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 1812
Study 22071710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1812
Study 19843338 — intervention group
Group type: COMPARATOR
Intervention: Low-fat PS-enriched soy beverage (2 g/serving)
Number of subjects: 56
Study 19843338 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat PS-enriched soy beverage (3.5 g/serving)
Number of subjects: 56
Study 16239059 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingicain Spray
Number of subjects: 104
Study 16239059 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingicaine Topical Anesthetic
Number of subjects: 104
Study 16239059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 16279276 — intervention group
Group type: EXPERIMENTAL
Intervention: Certification of clinical personnel for roles in the COMS
Number of subjects: 929
Study 16279276 — intervention group
Group type: EXPERIMENTAL
Intervention: Certification workload at the coordinating center
Number of subjects: 929
Study 16279276 — intervention group
Group type: EXPERIMENTAL
Intervention: Decertifications of clinical personnel
Number of subjects: 929
Study 11208677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycoprotein IIb/IIIa antagonists
Number of subjects: 33326
Study 9300508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 37
Study 9300508 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological intervention)
Number of subjects: 37
Study 8215000 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (10 cm of H2O) in patients without a patent foramen ovale (n = 39)
Number of subjects: 46
Study 8215000 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (10 cm of H2O) in patients with a patent foramen ovale (n = 7)
Number of subjects: 46
Study 3944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Early massive excision and grafting (within 72 hours of injury) with autograft overlaid with cadaveric allograft or cadaveric allograft alone
Number of subjects: 13
Study 3944837 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with daily hydrotherapy and twice daily applications of topical antimicrobial agents until granulating beds could receive autografts
Number of subjects: 13
Study 30053934 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 95
Study 30053934 — intervention group
Group type: COMPARATOR
Intervention: Aluminum Chloride
Number of subjects: 95
Study 27131611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic patients
Number of subjects: 8413
Study 24990034 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacle-based Four Square Step Test (FSST)
Number of subjects: 31
Study 22364823 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 0.4 mg/kg IV (prevention)
Number of subjects: 130
Study 22364823 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine 20 μg/kg IV (prevention)
Number of subjects: 130
Study 22364823 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 0.4 mg/kg IV (treatment)
Number of subjects: 130
Study 22364823 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine 20 μg/kg IV (treatment)
Number of subjects: 130
Study 20843249 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (initial doses based on weight)
Number of subjects: 1872
Study 20843249 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (higher doses)
Number of subjects: 1872
Study 20843249 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (poor responders)
Number of subjects: 1872
Study 18376119 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (at least 3 times a week for 8 weeks)
Number of subjects: 37
Study 15890990 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 10
Study 15890990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 12525526 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy arm (cisplatin and fluorouracil followed by surgery)
Number of subjects: 195
Study 12525526 — intervention group
Group type: COMPARATOR
Intervention: Control arm (surgery alone)
Number of subjects: 195
Study 10967380 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment combining polypectomy, intra‐maxillary intubation through the inferior meatus, macrolide administration
Number of subjects: 81
Study 9054757 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD ACLS
Number of subjects: 512
Study 9054757 — intervention group
Group type: COMPARATOR
Intervention: STD ACLS
Number of subjects: 512
Study 8317002 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic rectal temperature measurement with Ivac thermometer
Number of subjects: 157
Study 8317002 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic rectal temperature measurement with Ivac thermometer after calibration
Number of subjects: 157
Study 8317002 — intervention group
Group type: COMPARATOR
Intervention: Mercury thermometers
Number of subjects: 157
Study 3545909 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (96 mg in three divided doses for 7 days followed by a 2-day tapering)
Number of subjects: 43
Study 3545909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same regimen as methylprednisolone)
Number of subjects: 43
Study 3545909 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 43
Study 31653518 — intervention group
Group type: COMPARATOR
Intervention: High-altitude exposure
Number of subjects: 8
Study 28993396 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose feedback followed by biobehavioural feedback (glucose plus PA)
Number of subjects: 45
Study 28993396 — intervention group
Group type: EXPERIMENTAL
Intervention: PA feedback followed by biobehavioural feedback
Number of subjects: 45
Study 28993396 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobehavioural feedback
Number of subjects: 45
Study 28993396 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 45
Study 25591391 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine‐pyrimethamine plus azithromycin (SPAZ) monthly from second trimester
Number of subjects: 2793
Study 25591391 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine‐pyrimethamine and chloroquine (SPCQ) given once, followed by SPCQ placebo (control)
Number of subjects: 2793
Study 23429964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol 320 mg bid for 12 weeks
Number of subjects: 343
Study 23429964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 23429964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol 320 mg bid for 12 weeks (subgroup study)
Number of subjects: 343
Study 21166851 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 119
Study 21166851 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 119
Study 18811806 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary implants for LBBB
Number of subjects: 328
Study 18811806 — intervention group
Group type: COMPARATOR
Intervention: Upgrades from RVS
Number of subjects: 328
Study 18811806 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cohort (LBBB and RVS)
Number of subjects: 328
Study 16523371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal approach
Number of subjects: 44
Study 16523371 — intervention group
Group type: COMPARATOR
Intervention: Open anterior mesh repair
Number of subjects: 44
Study 16523371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 12911281 — intervention group
Group type: EXPERIMENTAL
Intervention: New AChR antibody test using a mixture of AChR from TE671‐ε and TE671‐γ cells
Number of subjects: 365
Study 12911281 — intervention group
Group type: COMPARATOR
Intervention: Standard assay using fetal type AChR
Number of subjects: 365
Study 10766581 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1200 mg weekly)
Number of subjects: 520
Study 10766581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 10766581 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 520
Study 9121823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain intensity (RIPP) in chronic pain patients
Number of subjects: 93